Kevin R.  Thornal net worth and biography

Kevin Thornal Biography and Net Worth

Insider of Hologic
Mr. Kevin R. Thornal has been a Division President of Cynosure at Hologic, Inc. since August 15, 2017. Mr. Thornal joined Hologic in August 2014 as Vice President of Customer Experience, Field Service & Clinical Applications for the Breast and Skeletal Health Division. He transitioned to Vice President, Breast and Skeletal Health for the Europe, Middle East and Africa Region at Hologic in early 2016. Prior to joining Hologic, Mr. Thornal worked at Stryker from 2004 to 2014 in positions of increasing responsibility in sales, marketing and mergers and acquisitions. Throughout his career, Mr. Thornal has established a track record of leading businesses that deliver strong growth and commercial excellence. Before joining the medical technology industry, Mr. Thornal played professional football, including a short stint with the Atlanta Falcons. He holds a Bachelor of Arts degree in History and minors in English and Secondary Education from Southern Methodist University.

What is Kevin R. Thornal's net worth?

The estimated net worth of Kevin R. Thornal is at least $3.16 million as of December 10th, 2020. Mr. Thornal owns 40,849 shares of Hologic stock worth more than $3,159,670 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Thornal may own. Learn More about Kevin R. Thornal's net worth.

How do I contact Kevin R. Thornal?

The corporate mailing address for Mr. Thornal and other Hologic executives is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. Hologic can also be reached via phone at (508) 263-2900 and via email at [email protected]. Learn More on Kevin R. Thornal's contact information.

Has Kevin R. Thornal been buying or selling shares of Hologic?

Kevin R. Thornal has not been actively trading shares of Hologic during the last ninety days. Most recently, Kevin R. Thornal sold 16,869 shares of the business's stock in a transaction on Thursday, December 10th. The shares were sold at an average price of $73.99, for a transaction totalling $1,248,137.31. Following the completion of the sale, the insider now directly owns 40,849 shares of the company's stock, valued at $3,022,417.51. Learn More on Kevin R. Thornal's trading history.

Who are Hologic's active insiders?

Hologic's insider roster includes Benjamin Cohn (Insider), Sally Crawford (Director), Sean Daugherty (Insider), Scott Garrett (Director), John Griffin (General Counsel), Stephen Macmillan (CEO), Essex Mitchell (Insider), Karleen Oberton (CFO), Kevin Thornal (Insider), Peter Valenti, III (Insider), and Jan Verstreken (Insider). Learn More on Hologic's active insiders.

Are insiders buying or selling shares of Hologic?

During the last twelve months, insiders at the medical equipment provider sold shares 7 times. They sold a total of 62,736 shares worth more than $4,696,732.85. The most recent insider tranaction occured on March, 14th when Director Scott T Garrett sold 16,441 shares worth more than $1,241,295.50. Insiders at Hologic own 1.8% of the company. Learn More about insider trades at Hologic.

Information on this page was last updated on 3/14/2024.

Kevin R. Thornal Insider Trading History at Hologic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/10/2020Sell16,869$73.99$1,248,137.3140,849View SEC Filing Icon  
See Full Table

Kevin R. Thornal Buying and Selling Activity at Hologic

This chart shows Kevin R Thornal's buying and selling at Hologic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Hologic Company Overview

Hologic logo
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $77.35
Low: $76.46
High: $77.37

50 Day Range

MA: $74.73
Low: $72.04
High: $77.35

2 Week Range

Now: $77.35
Low: $64.02
High: $87.88

Volume

1,270,206 shs

Average Volume

1,775,627 shs

Market Capitalization

$18.16 billion

P/E Ratio

36.66

Dividend Yield

N/A

Beta

1